What's Going On With Checkpoint Therapeutics (CKPT) Stock Nosediving?
Portfolio Pulse from Henry Khederian
Checkpoint Therapeutics Inc (CKPT) stock plummeted by 52.7% after receiving a complete response letter (CRL) from the FDA, which highlighted issues with a third-party manufacturer's inspection for their skin cancer treatment, cosibelimab. The CRL did not raise concerns about the treatment's effectiveness or safety. Checkpoint is optimistic about addressing the FDA's concerns and plans to launch cosibelimab in 2024.
December 18, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Checkpoint Therapeutics' stock price plunged following the FDA's CRL related to manufacturing issues for cosibelimab, despite no concerns over the drug's clinical data.
The significant drop in CKPT's stock price is a direct reaction to the FDA's CRL, which is a substantial regulatory hurdle. Although the issues are not related to the drug's effectiveness or safety, the delay in potential approval and market entry can negatively impact revenue and investor sentiment in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100